And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Under the circumstances, our agenda is decidedly modest. We plan to connect with some people using the latest technologies from the safety of our castle, promenade our new official mascot, and catch up on some reading. And what about you? This may be a good time to get a head start on spring cleaning. You could reach out to an older person who might welcome a little interaction. Or you could simply take the long view and imagine how the world is changing. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon.

Roche (RHHBY) is unable to meet demand for coronavirus testing kits but is unwilling to share key information with labs to help them carry out mass testing, Dutch News writes, citing Follow The Money. Most Dutch testing labs work with Roche equipment and depend on the company for supplies and, due to special deals known as a “vendor lock-in,” they are not able to turn to alternative sources to stock up on essential items. The shortage of a liquid used to break open cells is one reason why the Netherlands is not carrying out mass testing.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • If I recall Mr Trumps quote correctly (from last evening on Fox?), “There is no risk in using a drug that’s already approved.” Taken literally, as well as seriously, the results from the misuse of acetominaphine (aka the venerable Tylenol) would seem to contradict him.
    Ignore the known side effects and the fact that the best ‘anecdotally reported results’ were combined with another drug that needs to be used carefully, and caution is warranted. Hopefully, the results from the observational studies in NYC hospitals will provide positive results – but I suspect this will be an 80 pct solution at best, rather than “a miracle.” [ Note: If the President can say he’s “guessing but …” I can say I suspect. ]

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy